Novo Nordisk Stock Price Forecast
Novo Nordisk (NYSE:NVO) Rebuilds Market Confidence as Wegovy Pill, Restructuring, and Undervaluation Drive a 2026 Recovery Path
From Alzheimer’s Setback to Strategic Refocus on Obesity and Diabetes Core
Novo Nordisk (NYSE:NVO) shares rebounded 4.59% to $47.06 after an extended selloff that saw the stock hit a four-year low of $44.97, marking a steep decline from its 2024 peak of $112.52. The correction followed the company’s phase 3 Evoke and Evoke+ trials, where semaglutide—the active ingredient in Wegovy and Ozempic—failed to demonstrate statistical significance in slowing Alzheimer’s disease progression. While this news triggered a 10% premarket drop, it had little material impact on the firm’s underlying fundamentals….
